(2026). Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HR+HER2− Advanced Breast Cancer. Cancer Management and Research.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HR+HER2− Advanced Breast Cancer."
Cancer Management and Research 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HR+HER2− Advanced Breast Cancer."
Cancer Management and Research, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.